Change in pregnancy-associated multiple sclerosis relapse rates over time: a meta-analysis

Publication date: Available online 30 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Ruth Dobson, Vilija G. Jokubaitis, Gavin Giovannoni
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research

Related Links:

Publication date: Available online 3 July 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Jessica Qiu, D. Sean Riminton, Stephen W. Reddel, Todd A. Hardy
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
AbstractBackgroundRelapsing –remitting multiple sclerosis (RRMS) is an incurable disease characterised by relapses (periods of function loss) followed by full or partial recovery, and potential permanent disability over time. Many disease-modifying treatments (DMTs) exist that help reduce relapses and slow disease progressio n. Most are contraindicated during conception/pregnancy and some require a discontinuation period before trying to conceive. Although around three-quarters of people with RRMS are women, there is limited knowledge about how reproductive issues impact DMT preference.ObjectiveThe aim of this study ...
Source: The Patient - Patient-Centered Outcomes Research - Category: International Medicine & Public Health Source Type: research
AbstractMost disease-modifying drugs (DMDs) are contraindicated in pregnancy. Management of MS is especially challenging for pregnant patients, as withdrawal of DMDs leave the patient at risk of increased disease activity. We, a group of experts in MS care from countries in the Arab Gulf, present our consensus recommendations on the management of MS in these patients. Where possible, a patient planning pregnancy can be switched to a DMD considered safe in this setting. Interferon β now can be used during pregnancy, where there is a clinical need to maintain treatment, in addition to glatiramer acetate. Natalizumab (us...
Source: Neurology and Therapy - Category: Neurology Source Type: research
Authors: Andersen JB, Magyari M Abstract INTRODUCTION: Multiple sclerosis (MS) is a chronically progressive disease of the central nervous system. The relapsing form of the disease predominantly affects women with onset between the ages 20 to 40 years. Therefore, timing, choice, and treatment options should take pregnancy planning into consideration to accommodate both the needs and safety of the mother and health of the fetus. AREAS COVERED: In this review, the authors discuss and summarize the recent evidence of different pharmacotherapeutic possibilities in the treatment of women with MS. EXPERT OPI...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Publication date: Available online 2 June 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Fereshteh Ashtari, Roshanak Mehdipour, Vahid Shaygannejad, Nasrin Asgari
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Authors: Anagnostouli M, Markoglou N, Chrousos G Abstract Multiple sclerosis (MS) is a multifactorial, chronic, immune-mediated, and neurodegenerative disease, having a well-known hypothalamic-pituitary-adrenal (HPA) axis dysfunction. Several hormones have a great impact in the immune dysregulation, psychology, and cognitive status of patients with MS, as also in the fertility and response to treatment. In this comprehensive review, as an introduction, we mention basic data concerning MS: epidemiology, genetics, immunogenetics, epigenetics, pathophysiology, and neuroimmunology. Hormonal components of the disease ca...
Source: Hormones - Category: Endocrinology Tags: Hormones (Athens) Source Type: research
CONCLUSIONS: Patients diagnosed in recent years tend to have less severe multiple sclerosis, probably due to the fact that it is diagnosed in its milder stages together with the steady increase in the number of treatments available. PMID: 32436209 [PubMed - in process]
Source: Revista de Neurologia - Category: Neurology Authors: Tags: Rev Neurol Source Type: research
ConclusionsWhile limited by the small number of pregnancies and related data from the cladribine clinical development program, highlighting the need for further study, the observations made in the present analysis were generally consistent with epidemiological data on pregnancy outcomes for the general population or women with multiple sclerosis. There were no congenital malformations in pregnancies that occurred during cladribine treatment or within 6  months after the last dose. As the data available for cladribine-exposed pregnancies in patients with multiple sclerosis are limited, a non-interventional post-authori...
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
In conclusion, interferons, glatiramer acetate or natalizumab, do not appear to increase the risk for spontaneous abortions, pre-term birth or major congenital malformations. There were very few patients incl uded that were exposed to fingolimod, azathioprine and rituximab; therefore, these results cannot be generalized across drugs. Future studies including internal comparators are needed to enable treating physicians and their patients to decide on the best treatment options.
Source: Journal of Neurology - Category: Neurology Source Type: research
Conclusion Potential breast milk exposure to IFN-β or GA did not increase the risk of common adverse infant outcomes in the first year of life. Taken together with the benefits of breastfeeding and low biological plausibility of risk, women with MS who wish to resume IFN-β or GA postpartum can be encouraged to breastfeed.
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: Multiple sclerosis, Cohort studies Article Source Type: research
More News: Multiple Sclerosis | Neurology | Pregnancy